Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Brostallicin: Final Phase II data

Final data from an open-label, U.S. Phase II trial in 47 evaluable patients with metastatic TNBC showed that brostallicin plus cisplatin led to a 6-month PFS

Read the full 263 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE